Contributions
Abstract: PB2215
Type: Publication Only
Background
Multiple myeloma is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. Patients affected by multiple myeloma become chemo-resistant : hence, one of the main topics in clinical research is the quest for therapeutic alternatives to overcome refractory disease.
Aims
Since 2012, we have treated patients affected by Multiple Myeloma, relapsed and refractory to most of the therapeutic options available, with a chemotherapy based on a combination of pegylated liposomal doxorubicin, cyclophosphamide and dexamethasone (CED), at monthly doses respectively of 35 mg/m2 on day 1800 mg/m2 on day 1 and 20 mg/ m2 on days 1 - 4.
Methods
Twenty (20) patients ( 11men, 9 women), with a median age of 62 years, (range: 40-74) affected by advanced, relapsed and progressive multiple myeloma, whose median number of previous treatments was 3 lines (range 2 - 5) were treated with monthly CED courses (median number of courses : 3 ; rage : 3-10).
Results
Three patients (15%) had a complete remission (CR), in 11 patients (55 %) there was a partial response (PR); the disease remained stable in two patients (10%) and four patients (20%) did not benefit from CED treatment. Median response duration was 9 months (range : 4 - 25). The toxicity profile of CED was satisfactory: hematological toxicity (WHO grade 2) was observed in 6 patients (30%).There was 2 patients with gastrointestinal disturbances, one patient with infections, an episode of acute renal failure in one patient. One toxic death due to sepsis was noted.
Conclusion
These results can encourage further studies as they have been obtained in patient with severely advanced disease stage, previously not exposed to anthracyclines. The preliminary data point to a significant results in 50% of patients with particularly advanced disease.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Myeloma
Abstract: PB2215
Type: Publication Only
Background
Multiple myeloma is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. Patients affected by multiple myeloma become chemo-resistant : hence, one of the main topics in clinical research is the quest for therapeutic alternatives to overcome refractory disease.
Aims
Since 2012, we have treated patients affected by Multiple Myeloma, relapsed and refractory to most of the therapeutic options available, with a chemotherapy based on a combination of pegylated liposomal doxorubicin, cyclophosphamide and dexamethasone (CED), at monthly doses respectively of 35 mg/m2 on day 1800 mg/m2 on day 1 and 20 mg/ m2 on days 1 - 4.
Methods
Twenty (20) patients ( 11men, 9 women), with a median age of 62 years, (range: 40-74) affected by advanced, relapsed and progressive multiple myeloma, whose median number of previous treatments was 3 lines (range 2 - 5) were treated with monthly CED courses (median number of courses : 3 ; rage : 3-10).
Results
Three patients (15%) had a complete remission (CR), in 11 patients (55 %) there was a partial response (PR); the disease remained stable in two patients (10%) and four patients (20%) did not benefit from CED treatment. Median response duration was 9 months (range : 4 - 25). The toxicity profile of CED was satisfactory: hematological toxicity (WHO grade 2) was observed in 6 patients (30%).There was 2 patients with gastrointestinal disturbances, one patient with infections, an episode of acute renal failure in one patient. One toxic death due to sepsis was noted.
Conclusion
These results can encourage further studies as they have been obtained in patient with severely advanced disease stage, previously not exposed to anthracyclines. The preliminary data point to a significant results in 50% of patients with particularly advanced disease.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Myeloma